Vectura Group (VEC) Receives “Buy” Rating from Numis Securities
Numis Securities reissued their buy rating on shares of Vectura Group (LON:VEC) in a research report report published on Thursday. The brokerage currently has a GBX 170 ($2.27) price objective on the stock.
VEC has been the subject of a number of other reports. Royal Bank of Canada raised shares of Vectura Group to a sector performer rating and set a GBX 119 ($1.59) target price for the company in a report on Thursday, December 14th. Peel Hunt reaffirmed a hold rating and set a GBX 160 ($2.14) target price on shares of Vectura Group in a report on Tuesday, October 31st. JPMorgan Chase & Co. reduced their target price on shares of Vectura Group from GBX 180 ($2.41) to GBX 175 ($2.34) and set an overweight rating for the company in a report on Friday, November 10th. Panmure Gordon reaffirmed a buy rating and set a GBX 150 ($2.01) target price on shares of Vectura Group in a report on Thursday, November 9th. Finally, Shore Capital reaffirmed a buy rating on shares of Vectura Group in a report on Thursday, November 9th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Vectura Group currently has an average rating of Buy and an average price target of GBX 174 ($2.33).
Shares of Vectura Group (LON VEC) traded down GBX 2.30 ($0.03) during mid-day trading on Thursday, reaching GBX 117.90 ($1.58). 8,032,265 shares of the company’s stock were exchanged, compared to its average volume of 3,420,000. Vectura Group has a twelve month low of GBX 86.50 ($1.16) and a twelve month high of GBX 166.97 ($2.23).
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/vectura-group-vec-receives-buy-rating-from-numis-securities/1795992.html.
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.